Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma

Journal for ImmunoTherapy of Cancer

Efrem D Mandelcorn²  Anthony M Joshua¹  Nataly Pesin²  Leila Khoja¹  Joshua S Manusow² 

[1] Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada;University of Toronto Department of Ophthalmology and Vision Sciences, University Health Network/Toronto Western Hospital, 399 Bathurst Street, 6 East Room 415, Toronto M5T 2S8, Ontario, Canada

关键词: Melanoma-associated Retinopathy (MAR);    PD-1 inhibitor;    Retinal vasculitis;    Melanoma;    Vitreous metastasis;   

Others  :  1133526
DOI  :  10.1186/s40425-014-0041-1

 received in 2014-06-25, accepted in 2014-11-13,  发布年份 2014

【 摘 要 】

We report on a 36-year-old woman treated with the anti PD-1 antibody Pembrolizumab for metastatic cutaneous melanoma in the first line setting. She achieved a complete response and then relapsed with metastases to the vitreous cavity with an associated angiographically determined retinal vasculitis. Vitreous metastasis without choroidal involvement is unusual and may be due to individual cell extravasation, vitreous hemorrhage containing malignant cells, or direct spread through the optic nerve. This finding highlights the need for immune sanctuary sites to be monitored in the presence of PD-1 inhibition and we hypothesize that the use of PD-1 inhibitor potentiated the patient’s angiographically determined retinal vasculitis.

【 授权许可】

   
2014 Manusow et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Jaissle GB, Szurman P, Rohrbach JM, Gelisken F, Bartz-Schmidt KU: A case of cutaneous melanoma metastatic to the vitreous cavity: possible pathomechanism and review of the literature. Graefes Arch Clin Exp Ophthalmol 2007, 245:733-740.
• [2]Gündüz K, Shields JA, Shields CL, Eagle RC Jr: Cutaneous melanoma metastatic to the vitreous cavity. Ophthalmology 1998, 105:600-605.
• [3]Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC: CNS immune privilege: hiding in plain sight. Immunol Rev 2006, 213:48-65.
• [4]Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN, Hodi FS: Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012, 13:459-465.
• [5]Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A: Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma. N Engl J Med 2013, 369:134-144.
• [6]Rahimy E, Sarraf D: Paraneoplastic and non-paraneoplastic retinopathy and optic neuropathy: evaluation and management. Surv Ophthalmol 2013, 58:430-458.
• [7]Lu Y, Jia L, He S, Hurley MC, Leys MJ, Jayasundera T, Heckenlively JR: Melanoma-associated retinopathy: a paraneoplastic autoimmune complication. Arch Ophthalmol 2009, 127:1572-1580.
• [8]Usui Y, Okunuki Y, Hattori T, Kezuka T, Keino H, Ebihara N, Sugita S, Usui M, Goto H, Takeuchi M: Functional expression of B7H1 on retinal pigment epithelial cells. Exp Eye Res 2008, 86:52-59.
• [9]Menzies AM, Long GV: New combinations and immunotherapies for melanoma: latest evidence and clinical utility. Ther Adv Med Oncol 2013, 5:278-285.